Holostem Terapie Avanzate Srl joins Clust-ER Association “Life Sciences and Wellbeing”
MODENA, ITALY – June 2, 2017. Holostem Terapie Avanzate is founder member of the new Clust-ER “Life Sciences and Wellbeing” promoted by Emilia-Romagna Region
The Clust-ER Associations are communities of public and private bodies (research centres, businesses, training bodies) that share ideas, skills, tools, and resources to support the competitiveness of the most important production systems in Emilia-Romagna. It is a competitiveness that no longer relies on the ability of individual research centres or businesses to operate on the global market, but increasingly on the ability of the entire local system to be innovative and attractive.
In these Clust-ERs, research laboratories and centres for innovation belonging to the High Technology Network team up with the business system and the higher education system to make up the inter-disciplinary critical mass necessary to multiply opportunities and develop strategic projects with a high regional impact.
Founder members of the 7 Cluste-Ers (Agrifood, Building and Construction, Energy and Sustainable Development, Cultural and Creative Industries, Life Sciences and Wellbeing, Innovation in Services, Mechatronics and Motoristics) are 66 laboratories and 11 centres belonging to the regional High Technology Network, 23 businesses (Alma Automotive Srl, Anastasis Soc. Coop, Bio-Pro Srl, Bluegan Srl, Cat Progetti Srl, Camser, Capellini Srl, Chiesi Farmaceutici Spa, Digitalmech Srl, Dmlogica Srl, Doc Servizi Soc. Coop, EOStech Srl, Holostem Terapie Avanzate Srl, Inacqua soc. Coop, Jsb Solutions srl, Juno Design Srl, La Meccanica Padana Srl, Machining Centers Manufacturing Spa, Nextup Srl, Operatech, Sata Srl, Società Cooperativa Culture, Transmed Research Srl e Granarolo Spa), 4 training bodies and 8 other subjects.
- Newcastle pharmacy experts work with Italian biotech lab to provide access to sight-saving treatment across England
- Holostem Terapie Avanzate begins its transition to a Foundation
- Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
- Gene therapy for butterfly children: 5-year follow-up published in the New England Journal of Medicine
- Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa